General Meeting

Please select...

Proposed buyout of Novartis’ interest in GlaxoSmithKline Consumer Healthcare Holdings Limited

GSK will be holding a General Meeting on Thursday 3 May 2018 at the QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE to seek shareholder approval for the proposed buyout of Novartis’ interest in GlaxoSmithKline Consumer Healthcare Holdings Limited. The General Meeting will commence at 3.30pm or as soon thereafter as the Annual General Meeting convened for that date has concluded or been adjourned.

The Circular to Shareholders and Notice of General Meeting (PDF) gives details on the resolution to be put to the meeting, together with explanatory notes.

Previously published documents relating to the proposed transaction:

Webcast dated 27 March 2018:

In accordance with section 311A of the Companies Act 2006, GSK confirms that, as at 11 April 2018, its issued share capital (excluding Treasury shares) consisted of 4,959,130,058 ordinary shares of 25 pence each, carrying one vote each. Therefore, the total voting rights that members are entitled to exercise at the General Meeting in respect of these shares is 4,959,130,058.

Back to top